Naveni® PD1/PD–L1 BOND RX HRP

ILLUMINATING FUNCTION IN SPATIAL PROTEOMICS

Automated detection of PD1/PD-L1 interactions *in situ*

Immune checkpoint therapy (ICT) responses can vary among patients, underscoring the need for improved predictive biomarkers to refine patient stratification. Although PD-L1 immunohistochemistry (IHC) is widely used, the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear[1]. Preliminary data show that the PD1/PD-L1 interaction may be a predictive biomarker for ICT response in NSCLC, providing more information than the current clinical standard of PD-L1 IHC[2]. Now, Navinci introduces the Naveni® PD1/PD-L1 BOND RX HRP in collaboration with Leica Biosystems for enhanced reproducibility and throughput.

Naveni® PD1/PD-L1 BOND RX HRP enables you to:

- Visualize the precise interaction of PD1/PD-L1 within the tissue microenvironment.
- Evaluate the potential of PD1/PD-L1 interaction as a biomarker with a high throughput automated kit.
- Achieve heightened efficiency and reproducibility through an automated workflow, streamlining your research process.
- Save valuable time with the automated workflow, minimizing hands-on time and maximizing productivity.

In partnership with Leica Biosystems

For additional information and images, read more on navinci.se/technology/naveni-bond

Navinci

The Naveni® PD1/PD-L1 BOND HRP kit is based on the Naveni® *in situ* proximity ligation technology. The kit includes primary antibodies and two Navenibodies conjugated to oligo arms (depicted as orange antibodies in the illustration). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot. The kit is optimized and validated for the BOND RX Fully Automated Research Stainer. The kit has undergone thorough verification, including a diverse range of FFPE tissues, and a thorough comparative analysis at three distinct research sites, each utilizing their respective BOND RX systems, ensuring the establishment of robust performance characteristics across varied experimental settings.

PD1/PD-L1 interaction in head and neck cancer, Squamous cell carcinoma, visualized using Naveni® PD1/PD-L1 BOND RX HRP.

PD1/PD-L1 interaction in germinal centers, lymph node visualized using Naveni® PD1/PD-L1 BOND RX HRP.

Available from Navinci

Catalog nr	Kit	Target	Description
NAB.MR.030.H	Naveni PD1/PD-L1 BOND RX HRP	Human PD1/PD-L1 interaction	Navenibody targeting human PD1 protein based on clone EH33 CST Navenibody targeting human PD-L1 protein based on clone SP142 Abcam RabMAb® Buffers for blocking and dilutions and detection reagents for the PD1/PD-L1 interaction signal Reagents sufficient for 30 FFPE tissue slides, including dead volumes*
NA.PPI01.030.H	NaveniBright BOND RX HRP	Your choice, use primary antibodies with host origin of mouse and rabbit	Anti-mouse Navenibody Anti-rabbit Navenibody Buffers for blocking and dilutions and detection reagents Reagents sufficient for 30 FFPE tissue slides, including dead volumes*

*additional reagents required, read more on navinci.se/technology/naveni-bond
Research use only, not for use in diagnostic procedures

1) Sánchez-Magraner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res 80, 19 (2020)
2) Micke P, et al., PD1-PDL1 interaction as a superior predictor for response to immune checkpoint therapy in NSCLC patients. AACR 2024 7-10 April; San Diego (CA); Abstract nr 5139

In partnership with Leica Biosystems